Faizan Farooque

Faizan Farooque

Expertise: Real estate investment trusts (REITs), SPACs, Cryptocurrencies

Education: BSc (Hons) Degree in Applied Accounting, Oxford Brookes University; Introduction to Data Analysis Using Excel, Rice University; Excel Skills for Business: Intermediate, Macquarie University

About Faizan
Faizan Farooque is a finance journalist who has reported on the latest trends in the stock market for many years. He helps people by providing advice about saving and investing and keeping up with what’s happening in the financial world.

Faizan is writing for InvestorPlace.com, GuruFocus, and TipRanks and has previously worked as a financial journalist and data analyst for S&P Global. He can analyze company filings from sources like SEC, FINRA, and others to help identify potential investment opportunities. Researching specific industries is also something he does to provide industry insight for clients.

Faizan deeply understands the market and how to read the financial tea leaves to anticipate where things are headed. His expertise gives readers an insider’s perspective on what’s happening in the finance world so they can make smart decisions.

Recent Articles

Time for Luckin Coffee to Pick up the Pieces and Move On

There is more pain to come for Luckin stock, as more details emerge regarding the accounting scandal that rocked the Chinese coffee operator.

DraftKings Stock Offers Long-Term Value as Online Gaming Explodes

DraftKings stock will continue to grow at a healthy clip, as major sports leagues resume operations, and online betting explodes.

A Flawed Business Model Means Trouble for Naked Brand

NAKD stock will soon find its way to the pink sheets as the intimate apparel maker continues to operate a flawed business model.

Stay Bullish on United Airlines Stock, Even as Covid Cases Spike

United Airlines stock still has a lot left in the tank. The company has done enough to survive this crisis and streamline for the future.

Why iBio Is an Excellent Pandemic Spec Play

IBIO stock is on a bull run of epic proportions but there is little to suggest the biotech company can come up with a Covid-19 vaccine.